- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT07623759
Early Diagnostic Telehealth Pilot for Moderate- and High-Risk Children: Evaluating Assessment Protocols and Efficiency in Georgia's Early Intervention Program
Early Diagnostic Telehealth Pilot for Moderate- and High-risk Children: Evaluating Protocols for Children in Georgia's Early Intervention Program
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
The objective of this study is to develop, pilot, and evaluate a telehealth diagnostic protocol for assessing toddlers identified as moderate- or high-risk for autism spectrum disorder (ASD) within Georgia's Babies Can't Wait (BCW) Early Intervention (EI) program.
Many BCW children with moderate- or high-risk screening results face long wait times and limited access to diagnostic evaluations. This pilot will evaluate how many of these assessments can be completed entirely via a streamlined telehealth protocol and the level of diagnostic confidence achieved. It is hypothesized that the EDRM-E will increase access to timely, evidence-based autism evaluations and yield diagnostic outcomes comparable to in-person assessments based on DSM-5-TR criteria.
Secondary aims include identifying which additional assessment measures increase clinician confidence and are most acceptable to families and providers. It is hypothesized that moderate-risk children will require more in-depth evaluation and that families receiving expanded assessments will report higher satisfaction and acceptability.
A further objective is to examine family, BCW provider, and clinician satisfaction, understanding, and access to services following participation in the EDRM-E pilot. No data will be submitted to the FDA, and no algorithm, product, or software will be commercialized or used outside Emory.
Studientyp
Einschreibung (Geschätzt)
Phase
- Unzutreffend
Kontakte und Standorte
Studienkontakt
- Name: Allison J Schwartz, PhD
- Telefonnummer: 404-727-6865
- E-Mail: allison.schwartz@emory.edu
Studienorte
-
-
Georgia
-
Atlanta, Georgia, Vereinigte Staaten, 30322
- Emory University
-
Kontakt:
- Allison J Schwartz, PhD
- Telefonnummer: 404-727-6865
- E-Mail: allison.schwartz@emory.edu
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
- Kind
Akzeptiert gesunde Freiwillige
Beschreibung
Inclusion Criteria:
- Child is enrolled in a participating BCW district.
- Child is 16-36 months of age at the time of referral.
- Child is identified as moderate- or high-risk on the M-CHAT-R/F
- BCW provider submits a referral to the EDRM-E pilot by 33 months of age.
- Parent/guardian has basic English proficiency in order to complete intake forms and in-depth interview, and the child has exposure to English at home or in out-of-home care.
- Documentation of the M-CHAT-R/F screening results and parental consent to refer is completed and submitted.
Exclusion Criteria:
- Families making self-referrals to the EAC or referred from non-onboarded BCW districts.
- Child is older than 33 months at referral.
- Non-English speaking families due to staffing and resource limitations as the consent, parent interview and child assessment would need to be done and accessible in other languages and are not available within this study scope at this time. .
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Diagnose
- Zuteilung: N / A
- Interventionsmodell: Einzelgruppenzuweisung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Experimental: Families with children enrolled in BCW with suspected diagnosis of autism
Post-consent, families with children between 16-33 months will receive a link to complete the EAC Developmental History Survey on REDCap and a link to complete parent/caregiver questionnaires about developmental and/or adaptive information.
Children will be assessed via a remote telehealth session with an EAC clinician, using age-appropriate standardized measures.
Clinicians rate confidence after four points: intake review, parent interview and child observation, child assessment, and DSM-5-TR checklist completion.
Feedback is provided via telehealth, and a final report with recommendations is issued.
Psychologists will be asked about the protocol after each assessment.
Parents/caregivers will be asked to answer questions during the assessment, immediately after the assessment, and 3 months later.
EI providers will also be asked questions about their experience after the assessment.
Total length of enrollment range 3-16 weeks.
|
A telehealth diagnostic protocol for assessing toddlers identified as moderate- or high-risk for autism spectrum disorder (ASD) within Georgia's Babies Can't Wait (BCW) Early Intervention (EI) program.
This pilot will evaluate how many of the initial assessments can be completed entirely via a streamlined telehealth protocol and the level of diagnostic confidence achieved.
Andere Namen:
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Number of moderate and high-risk referral assessments that were completed entirely via a streamlined telehealth protocol
Zeitfenster: Monthly until the end of the study (approximately one year)
|
Number of moderate and high-risk referral assessments that can be completed entirely via streamlined telehealth protocol
|
Monthly until the end of the study (approximately one year)
|
|
Number of participants referred to the Early Diagnostic Response Model Expanded (EDRM-E)
Zeitfenster: End of study (up to 16 weeks post-intervention)
|
Monthly numbers of high-risk referrals to the EDRM-E pilot project and total number of referrals made to the EDRM-E at the end of the study.
|
End of study (up to 16 weeks post-intervention)
|
|
Number of participants consented in the Early Diagnostic Response Model Expanded (EDRM-E) study
Zeitfenster: Monthly until the end of the study (approximately one year)
|
Monthly number of families referred who consent to EDRM-E participation
|
Monthly until the end of the study (approximately one year)
|
|
Response rate in the Early Diagnostic Response Model Expanded (EDRM-E) study
Zeitfenster: Monthly until the end of the study (approximately one year)
|
Response rate will be calculated at project end using the formula [# of families who consented / # of families referred to project] x 100 = response rate)
|
Monthly until the end of the study (approximately one year)
|
|
Number of participants that completed the Early Diagnostic Response Model Expanded (EDRM-E) study
Zeitfenster: Every 3 months (Quarterly) until end of study (approximately one year)
|
Quarterly numbers of participants that completed the EDRM-E assessment protocol and total number of participants who completed EDRM-E assessment protocol at study conclusion
|
Every 3 months (Quarterly) until end of study (approximately one year)
|
|
Time from referral to completion of the program
Zeitfenster: Up to 12 weeks post-intervention
|
Individual calculation of time from BCW referral to final summary report sent to family using the formula: Date of Final Report sent to family - Date of referral from BCW =Time in EDRM-E pilot |
Up to 12 weeks post-intervention
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Anzahl der Teilnehmer mit zusätzlichen Informationen, die gesammelt wurden, um eine endgültige DSM-5-Schlussfolgerung zu ziehen
Zeitfenster: Alle 3 Monate (vierteljährlich) bis Studienende (ca. ein Jahr), bis zu 12 Wochen nach dem Eingriff
|
Anzahl der Teilnehmer mit zusätzlichen Informationen, die gesammelt wurden, um eine endgültige DSM-5-Schlussfolgerung zu ziehen
|
Alle 3 Monate (vierteljährlich) bis Studienende (ca. ein Jahr), bis zu 12 Wochen nach dem Eingriff
|
|
Anzahl der Familien, die bis zum Ende der Studie eine ASD-Bewertung durch das Pilotprojekt im Vergleich zu anderen Mitteln erhalten haben
Zeitfenster: Bis zum Abschluss des Studiums durchschnittlich 1 Jahr
|
Anzahl der Familien, die bis zum Ende der Studie eine ASD-Bewertung durch das Pilotprojekt im Vergleich zu anderen Mitteln erhalten haben
|
Bis zum Abschluss des Studiums durchschnittlich 1 Jahr
|
|
Number of moderate and high-risk referrals by BCW district
Zeitfenster: Every 3 months (Quarterly) until end of study (approximately one year), Up to 12 weeks post-intervention
|
Number of moderate-high risk referral assessments by specific BCW district.
Monthly, Quarterly, and Total numbers of participants who completed EDRM-E pilot assessment.
|
Every 3 months (Quarterly) until end of study (approximately one year), Up to 12 weeks post-intervention
|
|
Number of moderate and high-risk referral by child factors
Zeitfenster: Every 3 months (Quarterly) until end of study (approximately one year), Up to 12 weeks post-intervention
|
Number of high-risk referral assessments by child factors.
Monthly, Quarterly, and Total numbers of participants who completed EDRM-E pilot assessment.
|
Every 3 months (Quarterly) until end of study (approximately one year), Up to 12 weeks post-intervention
|
|
Number of moderate and high-risk referrals by clinician setting
Zeitfenster: Every 3 months (Quarterly) until end of study (approximately one year), Up to 12 weeks post-intervention
|
Number of high-risk referral assessments by clinician setting.
Monthly, Quarterly, and Total numbers of participants who completed EDRM-E pilot assessment.
|
Every 3 months (Quarterly) until end of study (approximately one year), Up to 12 weeks post-intervention
|
|
Parent satisfaction of EDRM-E assessment survey
Zeitfenster: At completion of EDRM-E assessment (4 weeks post-intervention)
|
Administered at the end of individual EDRM-E assessment.
Satisfaction surveys will use a Likert-scale of 1-5 with 1 being strongly disagree and 5 being strongly agree as well as 0 being not applicable/unknown.
Higher scores indicate more satisfaction with specific aspect of EDRM project.
Total score: 0 to 110.
|
At completion of EDRM-E assessment (4 weeks post-intervention)
|
|
BCW provider(s) Service Coordinator satisfaction with EDRM-E assessment survey
Zeitfenster: At completion of EDRM-E assessment (4 weeks post-intervention)
|
Administered at end of individual EDRM-E assessment.
Satisfaction surveys will use a Likert-scale of 1-5 with 1 being strongly disagree and 5 being strongly agree as well as 0 being not applicable/unknown.
Higher scores indicate more satisfaction with specific aspect of EDRM-E project.
|
At completion of EDRM-E assessment (4 weeks post-intervention)
|
|
Parent satisfaction with access to treatment survey
Zeitfenster: 3 months after completion of EDRM-E assessment
|
Parent satisfaction with access to treatment survey Administered 3-months after completion of EDRM-E assessment.
Satisfaction surveys will use a Likert-scale of 1-5 with 1 being strongly disagree and 5 being strongly agree as well as 0 being not applicable/unknown.
Higher scores indicate more satisfaction with specific aspect of EDRM-E project.
Total score: 0 to 15.
|
3 months after completion of EDRM-E assessment
|
|
BCW provider(s) Early Intervention Coordinator satisfaction with EDRM-E pilot survey
Zeitfenster: Every 3 months (Quarterly) until end of study (approximately one year), Up to 12 weeks postintervention
|
Completed every 3 months (Quarterly).
Satisfaction surveys will use a Likert-scale of 1-5 with 1 being strongly disagree and 5 being strongly agree as well as 0 being not applicable/unknown.
Higher scores indicate more satisfaction with specific aspect of EDRM project.
Total score: 0 to 55
|
Every 3 months (Quarterly) until end of study (approximately one year), Up to 12 weeks postintervention
|
|
Number of families screened moderate and high-risk for ASD and referred for an evaluation
Zeitfenster: Through study completion, an average of 1 year
|
Number of families screened moderate and high-risk for ASD and referred for an evaluation
|
Through study completion, an average of 1 year
|
Mitarbeiter und Ermittler
Sponsor
Mitarbeiter
Ermittler
- Hauptermittler: Allison J Schwartz, PhD, Emory University
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Geschätzt)
Primärer Abschluss (Geschätzt)
Studienabschluss (Geschätzt)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- 2026P000244
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Beschreibung des IPD-Plans
IPD-Sharing-Zeitrahmen
IPD-Sharing-Zugriffskriterien
Art der unterstützenden IPD-Freigabeinformationen
- STUDIENPROTOKOLL
- SAFT
- ICF
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Autismus-Spektrum-Störung
-
Kaleido BiosciencesBeendetVancomycin-resistente Enterococcus-, Extended-Spectrum-Beta-Lactamase-produzierende Enterobacteriaceae- oder Carbapenem-resistente Enterobacteriaceae-Kolonisierte PersonenVereinigte Staaten
-
University of BordeauxUnbekanntAssoziation von Darmmikrobiota mit ESBL-E-Kolonisierung und nachfolgender ESBL-E-Infektion (Microbe)Kritische Krankheit | Mikrobielle Besiedlung | Extended Spectrum Beta-Lactamase produzierende BakterieninfektionFrankreich
-
Chinese PLA General HospitalNoch keine RekrutierungNeuromyelitis Optica Spectrum -Erkrankung (NMOSD)China
-
University Hospital, Basel, SwitzerlandGebert Rüf-StiftungAktiv, nicht rekrutierendExtended Spectrum Beta-Lactamasen (ESBL) E. ColiSchweiz
-
Hospices Civils de LyonAbgeschlossenNeuromyelitis-Optica-Spektrum-Erkrankungen | Neuromyelitis optica Spectrum Related DisordersFrankreich
-
The Methodist Hospital Research InstituteM.D. Anderson Cancer Center; National Institute of Allergy and Infectious Diseases... und andere MitarbeiterRekrutierungAntibiotikaresistente Infektion | Clostridium difficile | Resistenz gegen antimikrobielle Medikamente | Carbapenem-resistente Enterobacteriaceae-Infektion | Vancomycin-resistente Enterokokken-Infektion | Vancomycin-resistente Enterokokken-Infektion | Carbapenem-resistente bakterielle Infektion | Extended Spectrum Beta-Lactamase produzierende BakterieninfektionVereinigte Staaten
-
Centre Hospitalier Universitaire VaudoisAbgeschlossenStevens-Johnson-Syndrom Toxic Epidermal Necrolysis Spectrum
-
Fondazione Policlinico Universitario Agostino Gemelli...Aktiv, nicht rekrutierendImpfung | Generalisierte Myasthenia gravis | Komplementsystem | Neuromyelitis Optica Spectrum -Erkrankung (NMOSD)Italien
-
Wuhan Union Hospital, ChinaNanjing Legend Biotech Co.RekrutierungMyasthenia gravis | Multiple Sklerose (MS) | Neuromyelitis Optica Spectrum -Erkrankung (NMOSD) | Anti-Myelin-Oligodendrozyten-Glykoprotein-Igg-assoziierte Störungen (Mogad)China
-
National Taiwan University HospitalUnbekanntChronische Graft-versus-Host-Krankheit | Sjögren-Syndrom | Schleimhautpemphigoid | Vernarbende Konjunktivitis | Stevens-Johnson-Syndrom Toxic Epidermal Necrolysis Spectrum | Verätzung des AugesTaiwan
Klinische Studien zur Early Diagnostic Response Model Expanded
-
Stanford UniversityJohn and Marcia Goldman FoundationNoch keine RekrutierungAutismus | Autismus-Spektrum-Störung (ASD)Vereinigte Staaten
-
Hôpital le VinatierHospices Civils de Lyon; University Hospital, Strasbourg, France; Versailles Hospital und andere MitarbeiterAbgeschlossenAutismus-Spektrum-StörungFrankreich
-
Bruno RhinerUniversity of Arkansas; West Virginia UniversityBeendetAutismus-Spektrum-StörungSchweiz